Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1003803 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1003803 0.1% lipophilic cream | EXPERIMENTAL | BAY1003803 0.1% lipophilic cream (on plaque and healthy skin) |
| BAY1003803 0.1% ointment | EXPERIMENTAL | BAY1003803 0.1% ointment (on plaque and healthy skin) |
| BAY1003803 0.01% lipophilic cream | EXPERIMENTAL | BAY1003803 0.01% lipophilic cream (on plaque and healthy skin) |
| BAY1003803 0.01% ointment | EXPERIMENTAL | BAY1003803 0.01% ointment (on plaque and healthy skin) |
| Clobetasol propionate | ACTIVE_COMPARATOR | Clobetasol propionate ointment 0.05 % (on plaque and healthy skin) |
| Betamethasone/calcipotriene | ACTIVE_COMPARATOR | Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin) |
| Name | Type | Description |
|---|---|---|
| BAY1003803 | DRUG | Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
| Clobetasol propionate | DRUG | Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
| Betamethasone/calcipotriene | DRUG | Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
Inclusion Criteria: * Male and female (non-childbearing potential) volunteer with stable plaque-type psoriasis, but otherwise healthy * Age: 18-64 years Exclusion Criteria: * Severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator * An...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
BAY1003803 is an investigational small molecule being developed for the treatment of psoriasis, a chronic skin condition. It is currently in Phase 1 clinical development and has been studied in a completed clinical trial in Germany.
BAY1003803 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY1003803 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
BAY1003803 has been studied in one completed Phase 1 clinical trial with the identifier NCT02940002. The trial, titled 'BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test,' enrolled 23 participants with psoriasis in Germany.